Physician profile
Ruben Ramirez
NPI 1053521989
$41,022.30
in general payments reported to CMS, 2019-2025
19 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $2,939 · 2021: $481 · 2022: $741 · 2023: $378 · 2024: $2,641 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $19K · Food and Beverage: $2,793 · Travel and Lodging: $1,048 · Education: $32.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,036.50 |
| Food and Beverage | $2,792.50 |
| Travel and Lodging | $1,047.57 |
| Education | $32.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $21,017.81 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $7,135.57 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $5,130.83 | 2019-2020 | |
| Exelixis INC. | $3,604.80 | 2019 | |
| Abbvie INC. | $1,264.76 | 2022-2025 | |
| Novo Nordisk INC | $1,174.44 | 2019-2025 | Ozempic |
| Biotissue Holdings INC. | $360.73 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $286.75 | 2019-2021 | |
| Eisai INC. | $238.67 | 2019 | |
| Phathom Pharmaceuticals, INC. | $180.62 | 2025 | Voquezna |
| Sirtex Medical INC | $152.67 | 2019-2022 | |
| Medtronic, INC. | $113.82 | 2021-2024 | Interstim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.49 | 2019-2023 | Xifaxan |
| Celgene Corporation | $97.49 | 2023-2024 | Zeposia |
| Dompe US, INC. | $58.52 | 2022-2025 | Oxervate |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $46.47 | 2020-2023 | |
| Redhill Biopharma INC. | $20.06 | 2020 | |
| Bausch & Lomb Americas INC. | $12.73 | 2022 | |
| Allergan, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruben Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.